https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in Science Advances detailing the company’s CRISPR-based Cellgorithm technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.
